WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Top HK official vows to advance Article 23 legislation at full speedA close look at 3rd ChinaChina through its own eyesWhite salt flats become black fertile fieldsOutlook positive as ChinaFishermen detail fatal rammingBook of Xi's Discourses on Financial Work PublishedChina vows to serve as world's stabilizing forceOfficials back warrants for HK fugitives abroadChinese FM mourns passing of renowned Japanese conductor Seiji Ozawa
2.9563s , 6516.0390625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Culture Circuit news portal